• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    June 18, 2024 - FDA Roundup: June 18, 2024

    6/18/24 3:16:28 PM ET
    $DLTR
    $AMGN
    Department/Specialty Retail Stores
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DLTR alert in real time by email
    For Immediate Release:
    June 18, 2024

    Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: 

    • Today, the FDA announced a request for input about patient safety associated with certain medical software functions excluded from the medical device definition. This input will help the FDA develop the 2024 report on the risks and benefits to health of non-device software functions. Please submit comments under docket number FDA-2018-N-1910 at www.regulations.gov by July 18, 2024.
    • The FDA recently issued a warning letter to Dollar Tree Inc., as an additional step following the investigation of lead and chromium in apple cinnamon fruit puree pouches this past fall that was prompted by findings of elevated blood lead levels in children. The FDA issued the warning letter to Dollar Tree, Inc., because, at the time of the recall, the company failed to adequately remove recalled WanaBana apple cinnamon fruit puree pouches from its store shelves. The FDA has asked the company to respond within 15 days of receipt of the warning letter stating the specific steps it has taken to address any violations and prevent the recurrence of violations or providing its reasoning and supporting information as to why the company believes it is not in violation of the law.
    • On Monday, FDA approved the vaccine, Capvaxive, for the following indications and use:
      • for the prevention of invasive disease caused by 22 different serotypes of Streptococcus pneumoniae covered by the vaccine for individuals 18 years of age and older.
      • for the prevention of pneumonia caused by 21 different serotypes of Streptococcus pneumoniae covered by the vaccine for individuals 18 years of age and older.
      Streptococcus pneumoniae, also known as pneumococcus, are bacteria that can infect the lungs causing pneumonia, but when they infect the blood (bacteremia) or the coverings of the brain or spinal cord (meningitis) it is called invasive pneumococcal disease. It can be a very serious disease. The vaccine is manufactured by Merck Sharp & Dohme LLC.
    • On Monday, the FDA announced the first of a series of five public meetings to provide educational sessions for stakeholders who are interested in the new animal drug approval process. The annual educational conferences the FDA will host over the next four years are described in the “Animal Drug User Fee Act Reauthorization Performance Goals and Procedures Fiscal Years 2024 Through 2028.” The first educational conference will be held on July 17, 2024, from 9 a.m. to 5 p.m. ET. Attendees can join in-person or virtually.   
    • On Monday, the FDA’s Center for Devices and Radiological Health published a new blog: The Promise of Artificial Intelligence for Improving Health Care. Artificial intelligence (AI) is rapidly changing the health care industry and holds transformative potential. Among the possibilities AI offers are significantly improving patient care and medical professional satisfaction, accelerating and advancing research in medical device development and drug discovery, and driving operational efficiency by enabling personalized treatment and streamlining health care processes. At the FDA, we know that the proper integration of AI across the health care ecosystem will be important to achieving its potential while reducing risks and challenges.
    • On Monday, the American Society of Addiction Medicine issued the draft “Clinical Practice Guideline on Benzodiazepine Tapering,” which is now available for public comment. The development of this guideline was funded by an FDA-provided grant and in partnership with the American Academy of Family Physicians, the American Academy of Neurology, the American Academy of Physician Associates, the American Association of Medical Toxicology, the American Association of Nurse Practitioners, the American Association of Psychiatric Pharmacists, the American College of Obstetricians and Gynecologists, the American Geriatrics Society, and the American Psychiatric Association.
    • On Monday, the FDA approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma. Adverse reactions associated with pembrolizumab and chemotherapy were generally similar to those previously reported for pembrolizumab or chemotherapy with the exception of a higher incidence of rash. See the prescribing information for complete adverse reactions. Full prescribing information for Keytruda will be posted on Drugs@FDA. 
    • On Friday, the FDA issued a Proposed Administrative Order: Amending Over-the-Counter Monograph M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use. The agency is issuing this FDA-initiated proposed administrative order (proposed order), to address a safety issue related to over-the-counter monograph drug products containing acetaminophen. This proposed order, if finalized, would require drug companies to add a warning to the labeling. Additional information can be found in the CDER Statement about this proposed order. 
    • On Friday, the FDA published a summary of the patient listening sessions held in March 2024 on Attention-Deficit/Hyperactivity Disorder (ADHD). The goal of the sessions is to help FDA’s staff better understand patient perspectives about their diagnosis and the risks and benefits associated with stimulant and non-stimulant treatment for ADHD.
    • On Friday, the FDA approved durvalumab (Imfinzi, AstraZeneca UK Limited) with carboplatin plus paclitaxel followed by single-agent durvalumab for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). The most common adverse reactions (>25%) with durvalumab in combination with carboplatin and paclitaxel were peripheral neuropathy, musculoskeletal pain, nausea, alopecia, fatigue, abdominal pain, constipation, rash, diarrhea, vomiting, and cough. Full prescribing information for Imfinzi will be posted on Drugs@ FDA..
    • On Friday, the FDA approved blinatumomab (Blincyto, Amgen Inc.) for adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (Ph-negative BCP ALL) in the consolidation phase of multiphase chemotherapy. In Study E1910, the most common adverse reactions (≥20%) in the blinatumomab arm were neutropenia, thrombocytopenia, anemia, leukopenia, headache, infection, nausea, lymphopenia, diarrhea, musculoskeletal pain, and tremor. In Study 20120215, the most common adverse reactions (≥20%) in the blinatumomab arm were pyrexia, nausea, headache, rash, hypogammaglobulinemia, and anemia. Full prescribing information for Blincyto will be posted on Drugs@FDA.

    Related Information

    Related Information
    • FDA Newsroom

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.


    Inquiries

    Media:
    FDA Office of Media Affairs
    888-INFO-FDA
    Consumer:
    888-INFO-FDA

     
    Get the next $DLTR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DLTR
    $AMGN

    CompanyDatePrice TargetRatingAnalyst
    Dollar Tree Inc.
    $DLTR
    9/3/2025$95.00Hold → Reduce
    Gordon Haskett
    Amgen Inc.
    $AMGN
    9/3/2025Mkt Perform
    Raymond James
    Dollar Tree Inc.
    $DLTR
    8/29/2025$100.00 → $130.00Market Perform → Outperform
    Telsey Advisory Group
    Dollar Tree Inc.
    $DLTR
    7/21/2025$111.00 → $138.00Overweight
    Analyst
    Dollar Tree Inc.
    $DLTR
    7/21/2025$138.00Equal Weight → Overweight
    Barclays
    Dollar Tree Inc.
    $DLTR
    7/17/2025$106.00Hold
    Jefferies
    Dollar Tree Inc.
    $DLTR
    6/5/2025$111.00Neutral → Overweight
    Analyst
    Dollar Tree Inc.
    $DLTR
    5/27/2025$82.00 → $95.00Market Perform
    Telsey Advisory Group
    More analyst ratings

    $DLTR
    $AMGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dollar Tree Announces Planned Merchandising Leadership Succession

    Brent Beebe to be promoted to Chief Merchandising Officer; Rick McNeely to retire in April 2026 Dollar Tree, Inc. (NASDAQ:DLTR), today announced that Brent Beebe, Senior Vice President of Merchandising and Marketing, will be promoted to Chief Merchandising Officer effective April 2026. He will succeed Rick McNeely, who will retire next spring following a distinguished career with Dollar Tree and across the retail industry. Mr. Beebe is joining the company's executive leadership team and will partner closely with Mr. McNeely over the next eight months to ensure a smooth and seamless transition. This press release features multimedia. View the full release here: https://www.businesswire.co

    9/9/25 8:00:00 AM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

    THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in adults and adolescents with moderate to severe atopic dermatitis (AD). The ongoing ASCEND study, which includes approximately 2,600 patients, is designed to evaluate the long-term safety and efficacy of rocatinlimab (150 mg and 300 mg) administered every four or eight weeks in individuals who completed a previous ROCKET program trial (IGNITE, HORIZON, SHUTTLE, ASTRO, ORBIT or VOYAGER). This analys

    9/9/25 12:12:26 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

    THOUSAND OAKS, Calif. and TOKYO, Sept. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in adults and adolescents with moderate to severe atopic dermatitis (AD). The ongoing ASCEND study, which includes approximately 2,600 patients, is designed to evaluate the long-term safety and efficacy of rocatinlimab (150 mg and 300 mg) administered every four or eight weeks in individuals who completed a previous ROCKET program trial (IGNITE, HORIZON, SHUTTLE, ASTRO, ORBIT or VOYAGER). This analysis focuse

    9/8/25 8:04:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DLTR
    $AMGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    11/21/24 12:43:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for PAVBLU issued to AMGEN INC

    Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

    8/26/24 5:53:38 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    8/21/24 12:12:47 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DLTR
    $AMGN
    SEC Filings

    View All

    Dollar Tree Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - DOLLAR TREE, INC. (0000935703) (Filer)

    9/9/25 8:00:56 AM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Amgen Inc.

    SCHEDULE 13G/A - AMGEN INC (0000318154) (Subject)

    9/8/25 11:06:01 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Dollar Tree Inc.

    10-Q - DOLLAR TREE, INC. (0000935703) (Filer)

    9/3/25 6:34:53 AM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    $DLTR
    $AMGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $DLTR
    $AMGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $DLTR
    $AMGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Glendinning Stewart bought $342,130 worth of shares (3,500 units at $97.75), increasing direct ownership by 7% to 52,853 units (SEC Form 4)

    4 - DOLLAR TREE, INC. (0000935703) (Issuer)

    9/9/25 5:14:56 PM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    Chief Accounting Officer Maheshwari Aditya bought $59,899 worth of shares (610 units at $98.19), increasing direct ownership by 14% to 4,841 units (SEC Form 4)

    4 - DOLLAR TREE, INC. (0000935703) (Issuer)

    6/20/25 2:48:55 PM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    Chief Financial Officer Glendinning Stewart bought $1,236,750 worth of shares (17,000 units at $72.75), increasing direct ownership by 53% to 49,353 units (SEC Form 4)

    4 - DOLLAR TREE, INC. (0000935703) (Issuer)

    4/16/25 3:36:28 PM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    Dollar Tree downgraded by Gordon Haskett with a new price target

    Gordon Haskett downgraded Dollar Tree from Hold to Reduce and set a new price target of $95.00

    9/3/25 1:54:36 PM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    Raymond James resumed coverage on Amgen

    Raymond James resumed coverage of Amgen with a rating of Mkt Perform

    9/3/25 8:26:50 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dollar Tree upgraded by Telsey Advisory Group with a new price target

    Telsey Advisory Group upgraded Dollar Tree from Market Perform to Outperform and set a new price target of $130.00 from $100.00 previously

    8/29/25 8:04:10 AM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    Chief Financial Officer Glendinning Stewart bought $342,130 worth of shares (3,500 units at $97.75), increasing direct ownership by 7% to 52,853 units (SEC Form 4)

    4 - DOLLAR TREE, INC. (0000935703) (Issuer)

    9/9/25 5:14:56 PM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    Director Stahl Stephanie sold $118,878 worth of shares (1,185 units at $100.32), decreasing direct ownership by 22% to 4,089 units (SEC Form 4)

    4 - DOLLAR TREE, INC. (0000935703) (Issuer)

    9/9/25 12:58:29 PM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    Chief Information Officer Aflatooni Robert covered exercise/tax liability with 543 shares, decreasing direct ownership by 2% to 22,662 units (SEC Form 4)

    4 - DOLLAR TREE, INC. (0000935703) (Issuer)

    8/27/25 5:41:42 PM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    $DLTR
    $AMGN
    Financials

    Live finance-specific insights

    View All

    Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

    THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in adults and adolescents with moderate to severe atopic dermatitis (AD). The ongoing ASCEND study, which includes approximately 2,600 patients, is designed to evaluate the long-term safety and efficacy of rocatinlimab (150 mg and 300 mg) administered every four or eight weeks in individuals who completed a previous ROCKET program trial (IGNITE, HORIZON, SHUTTLE, ASTRO, ORBIT or VOYAGER). This analys

    9/9/25 12:12:26 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

    THOUSAND OAKS, Calif. and TOKYO, Sept. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in adults and adolescents with moderate to severe atopic dermatitis (AD). The ongoing ASCEND study, which includes approximately 2,600 patients, is designed to evaluate the long-term safety and efficacy of rocatinlimab (150 mg and 300 mg) administered every four or eight weeks in individuals who completed a previous ROCKET program trial (IGNITE, HORIZON, SHUTTLE, ASTRO, ORBIT or VOYAGER). This analysis focuse

    9/8/25 8:04:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dollar Tree, Inc. Reports Results for the Second Quarter Fiscal 2025

    Dollar Tree Same-Store Net Sales +6.5% on +3.0% Traffic and +3.4% Ticket Diluted Earnings per Share (EPS) from Continuing Operations of $0.75 Adjusted Diluted EPS from Continuing Operations of $0.77, Including $0.20 of Positive Impact, Relative to Expectations, Related to Tariff Timing Completed Over $1 Billion of Share Repurchases Year-to-Date Increasing Full-Year Fiscal 2025 Net Sales Outlook Range to $19.3 to $19.5 Billion, Based on Comparable Store Net Sales Growth in the Range of 4% to 6% Updating Adjusted EPS from Continuing Operations Outlook Range to $5.32 to $5.72 to Reflect Current Operating Outlook and Year-to-Date Share Repurchases Completed Sale of Family Dol

    9/3/25 6:30:00 AM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    $DLTR
    $AMGN
    Leadership Updates

    Live Leadership Updates

    View All

    Dollar Tree Announces Legal Leadership Transition

    John S. Mitchell, Jr. Named Chief Legal Officer and Corporate Secretary Dollar Tree, Inc. (NASDAQ:DLTR), today announced a leadership transition in its Legal function. After two impactful years with the Company, Jonathan B. Leiken, Chief Legal Officer and Corporate Secretary, has made the decision to leave the Company to pursue another career opportunity. He will be succeeded by John S. Mitchell, Jr., who will assume the role of Dollar Tree's Chief Legal Officer and Corporate Secretary on Aug. 11, 2025. Mr. Leiken will remain with the Company until Aug. 22, 2025 to support Mr. Mitchell in the transition. "We are incredibly grateful for Jon Leiken's contributions during a pivotal period

    7/31/25 8:30:00 AM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer

    NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership TeamWill spearhead clinical advancement of the company's innovative NLRP3 inflammasome inhibitor portfolioBrings deep clinical leadership in obesity and cardiometabolic diseases, with a proven track record guiding programs from early-stage development through Phase 3 and regulatory approval Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appoi

    7/21/25 7:00:00 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dollar Tree Announces Chief Supply Chain Officer Transition

    Mike Kindy to retire from role as Chief Supply Chain Officer Roxanne Weng to assume role of Chief Supply Chain Officer Dollar Tree, Inc. (NASDAQ:DLTR) today announced that Chief Supply Chain Officer Mike Kindy will retire, and that Roxanne Weng has been appointed as the company's new Chief Supply Chain Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425441236/en/Mike Kindy, Retiring Chief Supply Chain Officer, Dollar Tree Mr. Kindy joined the company in May 2023 and played an integral role in advancing the company's supply chain initiatives. "Mike has been a driving force in retail supply chain for more than 35 ye

    4/28/25 8:00:00 AM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    $DLTR
    $AMGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Dollar Tree Inc.

    SC 13G/A - DOLLAR TREE, INC. (0000935703) (Subject)

    9/9/24 10:40:31 AM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    SEC Form SC 13G/A filed by Dollar Tree Inc. (Amendment)

    SC 13G/A - DOLLAR TREE, INC. (0000935703) (Subject)

    2/13/24 5:02:36 PM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

    SC 13G/A - AMGEN INC (0000318154) (Subject)

    2/13/24 4:58:51 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care